Lifeboat Foundation

Having more pixels could advance everything from biomedical imaging to astronomical observations.

Researchers at the National Institute of Standards and Technology (NIST) and their colleagues have built a superconducting camera containing 400,000 pixels — 400 times more than any other device of its type.

Superconducting cameras allow scientists to capture very weak light signals, whether from distant objects in space or parts of the human brain. Having more pixels could open up many new applications in science and biomedical research.

“As sensors continue to evolve to be more skin-like, there is a need for robots to be smarter. Developments in sensors and artificial intelligence will need to go hand in hand”

Scientists at the University of British Columbia and Honda’s research institute have revealed the creation of a revolutionary soft sensor that mimics human skin in a press release. This highly sensitive, smart, and stretchable sensor is poised to reshape how machines interact with the world.

Offering a myriad of applications, the soft sensor takes cues from human skin in terms of both sensitivity and texture. It can make actions such as picking up a piece of soft fruit possible when applied to the surface of a prosthetic or robotic arm.

A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.

For decades, researchers have believed that a class of drugs called microtubule poisons treat cancerous tumors by halting mitosis, or the division of cells. Now, a team of University of Wisconsin–Madison scientists has found that in patients, microtubule poisons don’t actually stop cancer cells from dividing. Instead, these drugs alter mitosis—sometimes enough to cause new cancer cells to die and the disease to regress.

Cancers grow and spread because cancerous cells divide and multiply indefinitely, unlike normal cells which are limited in the number of times they can split into new cells. The assumption that microtubule poisons stop cancer cells from dividing is based on lab studies demonstrating just that.

A meta-analysis showed improvement of neuropsychiatric symptoms with acetylcholinesterase inhibitors in Alzheimer disease and Parkinson disease, although effect sizes were small.

Neuropsychiatric symptoms are challenging to treat in patients with neurodegenerative conditions. In this meta-analysis, researchers investigated the effect of cholinesterase inhibitors (ChEI) on neuropsychiatric symptoms in those with Alzheimer disease (AD) or Parkinson disease (PD). Studies in the analysis included placebo-controlled, randomized clinical trials that included at least one ChEI — i.e., donepezil, rivastigmine, or galantamine — and applied at least one validated neuropsychiatric measure, with the Neuropsychiatric Inventory (NPI) being the most used measure studied. The primary outcomes were hallucinations and delusions. Secondary outcomes included all other neuropsychiatric outcomes.

Original participant data for 6,649 individuals with AD or PD from 17 trials were available for analysis out of 34 eligible trials. In patients with AD, ChEI use was associated with significantly fewer delusions (effect size, −0.08) and hallucinations (−0.09) compared with placebo. In the PD subgroup, ChEIs also were associated with significantly fewer delusions (−0.14) and hallucinations (−0.08). These effects did not differ among ChEI types. ChEIs were associated with lower appetite scores in the AD group and with significantly improved total neuropsychiatric scores in the PD group (−0.18). Increases in baseline neuropsychiatric scores were associated with greater effect size favoring ChEIs in those with PD. Lower baseline cognitive score was associated with increased effect size favoring ChEIs in both AD and PD.

Based on this meta-analysis, ChEIs could be considered in appropriate patients, since ChEIs may reduce hallucinations and delusions in people with AD or PD. Greater effects may be possible if neuropsychiatric symptoms or lower cognitive scores are present at the time of initiation. ChEIs decreased appetite scores in AD, which should be considered in those who are underweight. Whether ChEIs also improve neuropsychiatric symptoms in dementia with Lewy bodies requires further study, since data were insufficient to assess that population in this analysis.

Continue reading “Cholinesterase Inhibitors and Psychiatric Symptoms in Alzheimer Disease and Parkinson Disease” »

Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.

A breakthrough in treating cervical cancer is reported, with participants in a recent trial achieving a five-year survival rate of 80% – up from the previous average of 70%. The study used a combination of existing, cheap drugs ahead of usual radiotherapy treatment.

Cervical cancer cell illustration. Credit: PRB ARTS

Phase III of the INTERLACE trial, funded by Cancer Research UK and University College London (UCL) Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with cervical cancer. Researchers involved in the study presented the preliminary results at the recent European Society for Medical Oncology (ESMO) congress.

A collaborative team of researchers led by prof. Cees Dekker at TU Delft, in partnership with international colleagues, introduces a pioneering breakthrough in the world of nanomotors – the DNA origami nanoturbine. This nanoscale device could represent a paradigm shift, harnessing power from ion gradients or electrical potential across a solid-state nanopore to drive the turbine into mechanical rotations.

A study in human cell lines reveals cancer cells can activate a force-generating mechanism to survive a cancer therapy.

A team of researchers has developed a software tool called DANGER (Deleterious and ANticipatable Guides Evaluated by RNA-sequencing) analysis that provides a way for the safer design of genome editing in all organisms with a transcriptome. For about a decade, researchers have used the CRISPR technology for genome editing. However, there are some challenges in the use of CRISPR. The DANGER analysis overcomes these challenges and allows researchers to perform safer on-and off-target assessments without a reference genome. It holds the potential for applications in medicine, agriculture, and biological research.

Their work is published in the journal Bioinformatics Advances on August 23, 2023.

Genome editing, or gene editing, refers to technologies that allow researchers to change the genomic DNA of an organism. With these technologies, researchers can add, remove or alter genetic material in the genome.